OREANDA-NEWS. September 15, 2016.  Amgen (NASDAQ:AMGN)  today announced that the Company will host a webcast call for the investment community on Monday, Sept. 19, 2016, at 8:30 a.m. PT. 

Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate in the call to discuss results from the romosozumab phase 3 postmenopausal osteoporosis study (FRAME) presented at the American Society for Bone and Mineral Research Annual Meeting, and from the erenumab (AMG 334) Phase 2 chronic migraine study presented at the European Headache and Migraine Trust International Congress.

Live audio of the investor call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.